{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-019835","form_type":"8-K","ticker":"SCYX","cik":"0001178253","company_name":"SCYNEXIS INC","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.950754+00:00","generated_at":"2026-06-25T17:43:53.456969+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"SCYNEXIS Q1 net loss $5.5M; BREXAFEMME sales $0.7M; CANDLE study positive for rVVC","bullets":["Net loss $5.5M ($0.17/share) vs $4.7M ($0.18) in Q1 2021; product revenue $0.7M from BREXAFEMME.","Cash $95.2M at March 31; plus $42M net from April offering; runway into Q1 2024.","BREXAFEMME: ~4,000 prescriptions Q1, 1,800 HCPs; 55% commercial coverage (93M lives).","CANDLE Phase 3 met endpoint: 65.4% vs 53.1% placebo (p=0.02) for rVVC prevention; sNDA planned Q2 2022.","MARIO global Phase 3 initiated for invasive candidiasis; first patient enrollment expected Q2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-019835","json":"https://secwatch.observer/filing/0001564590-22-019835.json","markdown":"https://secwatch.observer/filing/0001564590-22-019835.md","text":"https://secwatch.observer/filing/0001564590-22-019835.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178253/000156459022019835/0001564590-22-019835-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178253/000156459022019835/scyx-8k_20220512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T17:43:53.456969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}